Conexiant’s news site is now MDSpire News. Learn more
Advertisement
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber
he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
Intracranial Hemorrhages, Central Nervous System Infections, Machine Learning
Dr. Jane Smith, MD, Neurocritical Care Physician, MD
Assistant Professor of Neurology
•
University Hospital of Critical Care Medicine
“While high internal AUCs like 0.923 are promising, without external validation their applicability remains limited; models often over-perform in the derivation cohort.”
Dr. Li Wei, PhD, Data Scientist & Neuroscience Researcher, PhD
Senior Research Fellow
•
Institute for Brain Health Research
“In many studies, predictive factors are selected via univariate analyses, but modern techniques like LASSO or embedded ML enhance feature selection and reduce bias.”
Dr. Maria Gonzalez, MPH, Infectious Disease Epidemiologist, MPH
Public Health Policy Advisor
•
National Stroke & Infection Control Coalition
“Models that stratify risk can direct resources efficiently—targeting prophylactic measures to those most likely to benefit, while reducing unnecessary antibiotic use in low-risk patients.”